Brookline Capital Management Forecasts KYMR Q2 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Equities research analysts at Brookline Capital Management issued their Q2 2025 earnings per share estimates for shares of Kymera Therapeutics in a research note issued on Thursday, February 27th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings per share of ($0.97) for the quarter. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. Brookline Capital Management also issued estimates for Kymera Therapeutics’ Q3 2025 earnings at ($1.03) EPS.

A number of other equities research analysts have also recently commented on the company. Leerink Partners restated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Friday, December 27th. BMO Capital Markets began coverage on Kymera Therapeutics in a report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price objective on the stock. Stephens reiterated an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. UBS Group lowered their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Finally, BTIG Research began coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $56.69.

Kymera Therapeutics Stock Down 3.8 %

NASDAQ:KYMR opened at $30.17 on Monday. Kymera Therapeutics has a 52 week low of $29.16 and a 52 week high of $53.27. The stock has a market capitalization of $1.95 billion, a PE ratio of -12.89 and a beta of 2.18. The stock’s 50-day moving average price is $38.81 and its 200-day moving average price is $43.66.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million.

Institutional Trading of Kymera Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. grew its stake in shares of Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after purchasing an additional 270 shares in the last quarter. State of Wyoming acquired a new stake in shares of Kymera Therapeutics during the fourth quarter worth about $45,000. GF Fund Management CO. LTD. acquired a new stake in shares of Kymera Therapeutics during the fourth quarter worth about $55,000. KBC Group NV increased its position in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after purchasing an additional 752 shares in the last quarter. Finally, Quarry LP acquired a new stake in shares of Kymera Therapeutics during the third quarter worth about $95,000.

Insiders Place Their Bets

In other news, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the sale, the insider now owns 54,826 shares of the company’s stock, valued at approximately $2,288,985.50. The trade was a 5.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the sale, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,788 shares of company stock valued at $455,202 in the last ninety days. 15.82% of the stock is currently owned by corporate insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.